Holen Sie sich die Stockscreener-App
91.22
0.38%
-0.35
Vorhandelsmarkt:
91.39
0.17
+0.19%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$91.57
Offen:
$91.165
24-Stunden-Volumen:
5.89M
Relative Volume:
1.12
Marktkapitalisierung:
$282.83B
Einnahmen:
$58.07B
Nettoeinkommen (Verlust:
$9.40B
KGV:
30.29
EPS:
3.0113
Netto-Cashflow:
$9.87B
1W Leistung:
-1.41%
1M Leistung:
+1.15%
6M Leistung:
+31.35%
1J Leistung:
+37.69%
1-Tages-Spanne:
$89.53
$91.38
1-Wochen-Bereich:
$89.53
$92.88
52-Wochen-Spanne:
$61.24
$94.02
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
91.22 | 283.92B | 58.07B | 9.40B | 9.87B | 3.0113 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
JP Morgan expects solid AstraZeneca quarter and reassuring outlook - Proactive Investors
AstraZeneca's Self-Injectable Lupus Drug Shines In Late-Stage Trial - Benzinga
Eyes on Asia: Insilico, Ipsen, AstraZeneca - BioXconomy
AstraZeneca flags positive trial data for Saphnelo as SLE treatment - marketscreener.com
Haleon Shares Added, AstraZeneca Removed From Goldman Sachs European Conviction List - AskTraders.com
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
AstraZeneca (AZN) Dropped from Goldman Sachs' European Convictio - GuruFocus
AstraZeneca PLC $AZN Stake Boosted by Allspring Global Investments Holdings LLC - MarketBeat
The Truth About AstraZeneca plc: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
Can AstraZeneca PLC ZEG stock sustain institutional flowsMarket Weekly Review & Daily Stock Trend Reports - moha.gov.vn
Key facts: AstraZeneca lowers drug prices for Medicaid; reports share count - TradingView — Track All Markets
AstraZeneca reports total voting rights of 1.55 billion shares - Investing.com
AstraZeneca reports total voting rights of 1.55 billion shares By Investing.com - Investing.com South Africa
Biological Therapies for Cancer Global Markets Report 2025-2030: Merck, BMS, Roche, AstraZeneca, Johnson & Johnson, and Novartis Drive Growth Through Pipeline Expansion and Strategic CollaborationsResearchAndMarkets.com - FinancialContent
Q4 EPS Estimates for AstraZeneca Boosted by Zacks Research - MarketBeat
My Personal CFO LLC Acquires Shares of 38,411 AstraZeneca PLC $AZN - MarketBeat
Zacks Research Raises Earnings Estimates for AstraZeneca - MarketBeat
25,322 Shares in AstraZeneca PLC $AZN Purchased by Moody Lynn & Lieberson LLC - MarketBeat
The Zacks Analyst Blog Highlights Berkshire Hathaway, AstraZeneca, Intel, Kingsway Financial and BK Technologies - Yahoo Finance
Smith Salley Wealth Management Raises Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Top Stock Reports for Berkshire Hathaway, AstraZeneca & Intel - Yahoo Finance
Ethic Inc. Acquires 11,638 Shares of AstraZeneca PLC $AZN - MarketBeat
Why AstraZeneca PLC (Common Stock) (ZEGA) stock appears on watchlistsHigh Frequency Trading Trends & Free Powerful Profit Generation - bollywoodhelpline.com
Valicenti Advisory Services Inc. Has $4.66 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
DAVENPORT & Co LLC Increases Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (AZN) Stock Price Today - CoinMarketCap
AstraZeneca stock holds steady as mixed news and technicals limit major moves - Traders Union
Robbins Farley Purchases 27,582 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca Reaches Settlement With MSN Labs Over Cancer Drug - Bloomberg Law News
Swedbank AB Buys 286,904 Shares of AstraZeneca PLC $AZN - MarketBeat
LSEG, Rolls-Royce, AstraZeneca and Rightmove spotlighted as investment bank eyes potential winners for 2026 - Proactive financial news
Here's Why Astrazeneca (AZN) is a Strong Value Stock - Yahoo Finance
AstraZeneca’s NSCLC combo fails to meet primary endpoint in Phase III trial - Clinical Trials Arena
FDA Flags Deadly Risks, AstraZeneca Pulls Andexxa From US Market - Sahm
AstraZeneca's Lung Cancer Combo Falls Short In Phase 3 Trial - Sahm
Jacobio signs $1.9B deal with Astrazeneca for pan-KRAS inhibitor - BioWorld MedTech
AstraZeneca Sues US Over Drugs for Medicare Price Cuts Round 2 - Bloomberg Law News
AstraZeneca (AZN) to Withdraw Andexxa from U.S. Market by Year's End - GuruFocus
AstraZeneca reports Phase III trial of ceralasertib and Imfinzi did not meet main goal - Investing.com Nigeria
AstraZeneca’s Synthetic Lethality Drug Combo Fails In Phase III Trial - Citeline News & Insights
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction - Investing.com
AstraZeneca director Nazneen Rahman sells 297 shares in London transaction By Investing.com - Investing.com South Africa
AstraZeneca (AZN) Benefits as U.S. Government Strikes Pharmaceutical Deals - GuruFocus
AstraZeneca (AZN) gains 10th FDA Breakthrough Therapy nod for Enhertu in HER2-positive early breast cancer - Stock Titan
AstraZeneca (LON:AZN) Insider Sells £40,083.12 in Stock - MarketBeat
FDA grants breakthrough therapy designation to AstraZeneca’s ENHERTU for HER2-positive early breast cancer - Investing.com UK
AstraZeneca PLCEnhertu granted BTD for post-neoadjuvant early BC - Research Tree
AstraZeneca Starts Phase 3 Post-Surgery Endometrial Cancer Trial - marketscreener.com
Jacobio Strikes New Cancer Drug Deal with AstraZeneca - marketscreener.com
AstraZeneca, Jacobio Pharma Sign Global License Deal for Pan-KRAS Inhibitor - marketscreener.com
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView — Track All Markets
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):